Pristinamycin

Summary

Pristinamycin is an oral prescription antibiotic that belongs to the streptogramin class, a mixture of two synergistic components (group A macrolactone and group B cyclic depsipeptide). It is employed for infections caused by Gram‑positive bacteria that are resistant to many other drugs, including methicillin‑resistant Staphylococcus aureus (MRSA) and Mycoplasma genitalium, and has been examined for skin infections such as cellulitis and erysipelas. The drug is approved for human use and is taken by mouth.

Mechanism of Action

The two components of pristinamycin bind separate sites on the bacterial 50S ribosomal subunit. The group‑A molecule blocks the early phase of peptide‑chain elongation, while the group‑B molecule inhibits a later transpeptidation step. When both are present they act synergistically, producing an irreversible halt to protein synthesis and rapid bactericidal activity against susceptible Gram‑positive organisms. This dual‑binding pattern also limits cross‑resistance with macrolides and other ribosomal inhibitors.

What the Research Shows

A 2016 systematic overview of treatments for MRSA listed pristinamycin among five interventions evaluated for effectiveness and safety, indicating it is considered a therapeutic option for resistant Staphylococcus infections. A 2023 review of sexually transmitted infections highlighted pristinamycin as one of the limited oral alternatives for macrolide‑resistant Mycoplasma genitalium, citing its use when other agents fail. The 2022 European guideline for M. genitalium recommended a 10‑day course of pristinamycin (≈75% cure) as a third‑line regimen after azithromycin and moxifloxacin. A 2024 network meta‑analysis of cellulitis and erysipelas trials found pristinamycin achieved the highest cure rate for erysipelas, although it was associated with a higher incidence of rash compared with other antibiotics. Together, these sources suggest activity against multidrug‑resistant Gram‑positive pathogens and utility in specific resistant infections, but the evidence base is largely derived from guidelines and meta‑analyses rather than large, head‑to‑head randomized trials.

Reported Benefits

Clinical overviews and guideline panels recognize pristinamycin as active against multidrug‑resistant Gram‑positive bacteria, including MRSA, and as an oral option for macrolide‑resistant Mycoplasma genitalium, where it achieves cure rates around 75% in third‑line use. In a network meta‑analysis of skin infections, pristinamycin showed the highest cure proportion for erysipelas among the agents studied. Its dual‑component mechanism provides synergistic bactericidal activity and a low likelihood of cross‑resistance with macrolides, making it valuable when other oral agents are ineffective.

Limitations of the Evidence

High‑quality comparative data are limited; most evidence comes from systematic overviews, expert guidelines, and a network meta‑analysis rather than large randomized controlled trials dedicated to pristinamycin. Its use is confined to oral formulations, and historical poor water solubility restricted broader development. Safety data are sparse, with the meta‑analysis noting an increased risk of rash, and adverse‑event profiles are inferred from related streptogramin products rather than direct pristinamycin trials. Consequently, definitive dosing, duration, and comparative efficacy conclusions remain uncertain.

Safety Considerations

Reported adverse effects for oral pristinamycin include a higher incidence of rash compared with many other antibiotics used for erysipelas. While detailed safety data are limited, related streptogramin agents have been associated with arthralgia, myalgia, and infusion‑related pain (the latter relevant to injectable formulations). No major organ toxicity has been highlighted in the available literature, but clinicians should monitor patients for cutaneous reactions and consider hepatic function, given the hepatic metabolism of streptogramins in general.

How It Is Administered

Pristinamycin is administered orally as a tablet or suspension. It is formulated as a fixed‑ratio mixture of the two streptogramin components and is taken by mouth, typically multiple times daily, in accordance with prescribing information. No injectable or topical formulations are currently marketed.

Routes of Administration

Goals & Uses

• Treatment of MRSA infectionsAntimicrobialModerate
• Community-acquired pneumonia (mild)Respiratory InfectionLow
• treat bacterial infectionsInfectious DiseaseHigh
• Treatment of streptococcal infectionsAntimicrobial / Infectious DiseaseHigh
• Penicillin-allergic patient infectionsAntimicrobial / Infectious DiseaseModerate
• Treatment of staphylococcal skin and soft tissue infectionsAntimicrobial / Infectious DiseaseHigh

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Hypersensitivity to pristinamycin or other streptograminsAllergyHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Pregnancy (especially first trimester)ReproductiveModerate
• Hypersensitivity to streptograminsAllergyHigh

Adverse Effects

• Gastrointestinal upsetGastrointestinalCommon
• AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
• Skin rash / urticariaDermatologicalUncommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalCommonForceful expulsion of stomach contents
• Rash/pruritusDermatologicUncommon
• Elevated liver enzymesHepaticRareIncrease in AST/ALT or other hepatic markers
• DiarrheaGastrointestinalCommonLoose or frequent stools

Drug Interactions

• CYP3A4 inhibitors (e.g., erythromycin, clarithromycin)Moderate
• WarfarinModerate
• CyclosporineHigh
• Ergot alkaloidsHigh
• Statins (e.g., simvastatin)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Pediatric patients (< 6 years)PediatricRelative
• BreastfeedingReproductiveRelative
• Children <12 yearsAgeRelative

Regulatory Status

• European UnionApprovedApproved: respiratory tract infections, skin and soft‑tissue infectionsApproved for oral use in adult patients
• United StatesUnapprovedNot FDA‑approved; analogous synthetic product (quinupristin/dalfopristin) is approved
• United KingdomApprovedApproved: respiratory infections, skin infectionsAvailable under prescription

Approved in France (brand name Pyostacine) since the 1960s; not approved by the US FDA or EMA as a standalone product. Quinupristin/dalfopristin, a semi-synthetic IV derivative, is FDA-approved. Pristinamycin is used primarily in France and some European countries.

Evidence & Sources

• MRSA: treating people with infection
  Journal ArticleModerateRae N, et al.2016-01-01T00:00:00.000000Z
• Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, Mycoplasma genitalium, and syphilis
  Journal ArticleModerateMitjà O, et al.2023-01-01T00:00:00.000000Z
• Novel streptogramin antibiotics
  Journal ArticleModerateBonfiglio G, Furneri PM2001-01-01T00:00:00.000000Z
• Quinupristin-dalfopristin: an overview
  Journal ArticleModerateDelgado G Jr, et al.2000-01-01T00:00:00.000000Z
• 2021 European guideline on the management of Mycoplasma genitalium infections
  Journal ArticleLowJensen JS, et al.2022-01-01T00:00:00.000000Z
• Efficacy and safety of first- and second-line antibiotics for cellulitis and erysipelas: a network meta-analysis of randomized controlled trials
  Journal ArticleHighShu Z, et al.2024-01-01T00:00:00.000000Z

Frequently Asked Questions